Isoproterenol, an adrenergic β receptor agonist, induces metallothionein synthesis followed by canceling amyloid β1-42-induced neurodegeneration

Blockage of metallothionein synthesis via adrenaline β receptor activation invalidates dehydroeffusol-mediated prevention of amyloid β1-42 toxicity

Dehydroeffusol, a major phenanthrene in Juncus effusus, protects neurodegeneration induced by intracellular Zn2+ ferried by extracellular amyloid β1-42 (Aβ1-42). Here we focused on adrenaline β receptor activation and the induction of metallothioneins (MTs), intracellular Zn2+-binding proteins to test the protective mechanism of dehydroeffusol. Isoproterenol, an agonist of adrenergic β receptors elevated the level of MTs in the dentate granule cell layer 1 day after intracerebroventricular (ICV) injection. When Aβ1-42 was injected 1 day after isoproterenol injection, pre-injection of isoproterenol protected Aβ1-42 toxicity via reducing the increase in intracellular Zn2+ after ICV injection of Aβ1-42. On the basis of the effect of increased MTs by isoproterenol, dehydroeffusol (15 mg/kg body weight) was orally administered to mice once a day for 2 days. On day later, dehydroeffusol elevated the level of MTs and prevented Aβ1-42 toxicity via reducing Aβ1-42-mediated increase in intracellular Zn2+. In contrast, propranolol, an antagonist of adrenergic β receptors reduced the level of MTs increased by dehydroeffusol, resulting in invalidating the preventive effect of dehydroeffusol on Aβ1-42 toxicity. The present study indicates that blockage of MT synthesis via adrenaline β receptor activation invalidates dehydroeffusol-mediated prevention of Aβ1-42 toxicity. It is likely that MT synthesis via adrenaline β receptor activation is beneficial to neuroprotection and that oral intake of dehydroeffusol preventively serves against the Aβ1-42 toxicity.

Drug repurposing for neurodegenerative diseases using Zebrafish behavioral profiles

Drug repurposing can accelerate drug development while reducing the cost and risk of toxicity typically associated with de novo drug design. Several disorders lacking pharmacological solutions and exhibiting poor results in clinical trials - such as Alzheimer's disease (AD) - could benefit from a cost-effective approach to finding new therapeutics. We previously developed a neural network model, Z-LaP Tracker, capable of quantifying behaviors in zebrafish larvae relevant to cognitive function, including activity, reactivity, swimming patterns, and optomotor response in the presence of visual and acoustic stimuli. Using this model, we performed a high-throughput screening of FDA-approved drugs to identify compounds that affect zebrafish larval behavior in a manner consistent with the distinct behavior induced by calcineurin inhibitors. Cyclosporine (CsA) and other calcineurin inhibitors have garnered interest for their potential role in the prevention of AD. We generated behavioral profiles suitable for cluster analysis, through which we identified 64 candidate therapeutics for neurodegenerative disorders.

Finding Drug Repurposing Candidates for Neurodegenerative Diseases using Zebrafish Behavioral Profiles

Drug repurposing can accelerate drug development while reducing the cost and risk of toxicity typically associated with de novo drug design. Several disorders lacking pharmacological solutions and exhibiting poor results in clinical trials - such as Alzheimer's disease (AD) - could benefit from a cost-effective approach to finding new therapeutics. We previously developed a neural network model, Z-LaP Tracker, capable of quantifying behaviors in zebrafish larvae relevant to cognitive function, including activity, reactivity, swimming patterns, and optomotor response in the presence of visual and acoustic stimuli. Using this model, we performed a high-throughput screening of FDA-approved drugs to identify compounds that affect zebrafish larval behavior in a manner consistent with the distinct behavior induced by calcineurin inhibitors. Cyclosporine (CsA) and other calcineurin inhibitors have garnered interest for their potential role in the prevention of AD. We generated behavioral profiles suitable for cluster analysis, through which we identified 64 candidate therapeutics for neurodegenerative disorders.

A PAM of the α1A-Adrenergic receptor rescues biomarker, long-term potentiation, and cognitive deficits in Alzheimer's disease mouse models without effects on blood pressure

α1-Adrenergic Receptors (ARs) regulate the sympathetic nervous system by the binding of norepinephrine (NE) and epinephrine (Epi) through different subtypes (α1A, α1B, α1D). α1A-AR activation is hypothesized to be memory forming and cognitive enhancing but drug development has been stagnant due to unwanted side effects on blood pressure. We recently reported the pharmacological characterization of the first positive allosteric modulator (PAM) for the α1A-AR with predictive pro-cognitive and memory properties. In this report, we now demonstrate the in vivo characteristics of Compound 3 (Cmpd-3) in two genetically-different Alzheimer's Disease (AD) mouse models. Drug metabolism and pharmacokinetic studies indicate sufficient brain penetrance and rapid uptake into the brain with low to moderate clearance, and a favorable inhibition profile against the major cytochrome p450 enzymes. Oral administration of Cmpd-3 (3-9 mg/kg QD) can fully rescue long-term potentiation defects and AD biomarker profile (amyloid β-40, 42) within 3 months of dosing to levels that were non-significant from WT controls and which outperformed donepezil (1 mg/kg QD). There were also significant effects on paired pulse facilitation and cognitive behavior. Long-term and high-dose in vivo studies with Cmpd-3 revealed no effects on blood pressure. Our results suggest that Cmpd-3 can maintain lasting therapeutic levels and efficacy with disease modifying effects with a once per day dosing regimen in AD mouse models with no observed side effects.

Metallothionein synthesis increased by Ninjin-yoei-to, a Kampo medicine protects neuronal death and memory loss after exposure to amyloid β1-42

BACKGROUND

It is possible that increased synthesis of metallothioneins (MTs), Zn²⁺-binding proteins is linked with the protective effect of Ninjin-yoei-to (NYT) on Zn²⁺ toxicity ferried by amyloid β_1-42 (Aβ_1-42).

METHODS

Judging from the biological half-life (18-20 h) of MTs, the effective period of newly synthesized MT on capturing Zn²⁺ is estimated to be approximately 2 days. In the present paper, a diet containing 3% NYT was administered to mice for 2 days and then Aβ_1-42 was injected into the lateral ventricle of mice.

RESULTS

MT level in the dentate granule cell layer was elevated 2 days after administration of NYT diet, while the administration reduced intracellular Zn²⁺ level increased 1 h after Aβ_1-42 injection, resulting in rescuing neuronal death in the dentate granule cell layer, which was observed 14 days after Aβ_1-42 injection. Furthermore, Pre-administration of NYT diet rescued object recognition memory loss via affected perforant pathway long-term potentiation after local injection of Aβ_1-42 into the dentate granule cell layer of rats.

CONCLUSION

The present study indicates that pre-administration of NYT diet for 2 days increases synthesis of MTs, which reduces intracellular Zn²⁺ toxicity ferried by extracellular Aβ_1-42, resulting in protecting neuronal death in the dentate gyrus and memory loss after exposure to Aβ_1-42.

[Brain Function and Pathophysiology Focused on Zn2+ Dynamics]

The basal levels of intracellular Zn²⁺ and extracellular Zn²⁺ are in the range of ～100 pM and ～10 nM, respectively, in the brain. Extracellular Zn²⁺ dynamics is involved in both cognitive performance and neurodegeneration. The bidirectional actions are linked with extracellular glutamate and amyloid-β_1-42 (Aβ_1-42). Intracellular Zn²⁺ signaling via extracellular glutamate is required for learning and memory, while intracellular Zn²⁺ dysregulation induces cognitive decline. Furthermore, human Aβ_1-42, a causative peptide in Alzheimer's disease pathogenesis captures extracellular Zn²⁺ and readily taken up into hippocampal neurons followed by intracellular Zn²⁺ dysregulation. Aβ_1-42-mediated intracellular Zn²⁺ dysregulation is accelerated with aging, because extracellular Zn²⁺ is age-relatedly increased, resulting in Aβ_1-42-induced cognitive decline and neurodegeneration with aging. On the other hand, metallothioneins, zinc-binding proteins can capture Zn²⁺ released from intracellular Zn-Aβ_1-42 complexes and serve for intracellular Zn²⁺-buffering to maintain intracellular Zn²⁺ homeostasis. This review summarizes Zn²⁺ function and its neurotoxicity in the brain, and also the potential defense strategy via metallothioneins against Aβ_1-42-induced pathogenesis.